Zurich Cantonal Bank
SRPT icon

Zurich Cantonal Bank’s Sarepta Therapeutics SRPT Stock Holding History

Zurich Cantonal Bank’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,454
Closed -$655K – 3388
2025
Q4 		$655K Buy
+30,454
New +$642K ﹤0.01% 1607

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Zurich Cantonal Bank's SRPT Position: Q2 2026 in Review

Zurich Cantonal Bank held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 36,221 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #1799.

Zurich Cantonal Bank first reported a position in SRPT in Q2 2015 and has held it in 44 quarters since. The position peaked at $4.37M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Zurich Cantonal Bank held 36,221 shares of Sarepta Therapeutics worth $651K as of Q2 2026.
  • Zurich Cantonal Bank left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1799 holding.
  • Zurich Cantonal Bank first reported a position in Sarepta Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • Zurich Cantonal Bank's Sarepta Therapeutics position peaked at $4.37M in Q4 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.